Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
San Gabriel Valley Index
San Gabriel Valley
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Daiichi Sankyo Ltd ADR
(OP:
DSNKY
)
39.17
UNCHANGED
Streaming Delayed Price
Updated: 3:58 PM EDT, Aug 15, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
0
Open
39.17
Bid (Size)
N/A (0)
Ask (Size)
N/A (0)
Prev. Close
39.17
Today's Range
39.17 - 39.17
52wk Range
23.72 - 40.95
Shares Outstanding
N/A
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
DSNKY Stock Earnings: Daiichi Sankyo Co Reported Results for Q1 2024
August 13, 2024
Daiichi Sankyo Co just reported results for the first quarter of 2024.
Via
InvestorPlace
Recession-Resilient Asian Stock Picks: TSMC, SK Hynix Among This Analyst's Top 10
August 07, 2024
"As stock pickers, we focus on a basket of stocks that we believe will emerge from the current drawdown," strategists say.
Via
Benzinga
Performance
YTD
+44.59%
+44.59%
1 Month
+2.50%
+2.50%
3 Month
+11.98%
+11.98%
6 Month
+21.50%
+21.50%
1 Year
+33.55%
+33.55%
More News
Read More
Merck's Q2 Earnings: Revenue And EPS Beat Helped By Strong Keytruda Sales, But Acquisition Costs Bites Into Annual Profit Forecast
July 30, 2024
Via
Benzinga
Exposures
Product Safety
The 3 Most Undervalued Nasdaq 100 Stocks to Buy in July 2024
July 15, 2024
Via
InvestorPlace
FDA Declines To Approve Merck-Daiichi Sankyo Partnered Lung Cancer Drug
June 27, 2024
Via
Benzinga
Exposures
Product Safety
Daiichi, Zymeworks Terminate Seven Year-Cancer Antibody Pact
March 20, 2023
Via
Benzinga
Daiichi Sankyo Seeks Approval In Japan For Its mRNA-Based COVID-19 Vaccine
January 13, 2023
Via
Benzinga
Why Is AstraZeneca Stock Trading Lower On Tuesday?
May 28, 2024
Via
Benzinga
DSNKY Stock Earnings: Daiichi Sankyo Co Reported Results for Q3 2023
April 30, 2024
Via
InvestorPlace
Double Good News For AstraZeneca's Breast Cancer Drugs
April 29, 2024
Via
Benzinga
AstraZeneca/Daiichi's Flagship Drug Enhertu Secures Accelerated FDA Approval For Pretreated Cancer Patients With Solid Tumor
April 08, 2024
Via
Benzinga
Exposures
Product Safety
What's Going On With Pfizer Stock Today?
January 25, 2024
Via
Benzinga
Why Pharmaceutical Company Esperion Therapeutics Shares Are Diving Today
January 03, 2024
Via
Benzinga
Japan Emerges As Promising 2024 Investment Destination: 3 Stocks To Consider
December 20, 2023
Via
Benzinga
Merck Just Made a Big Move -- but Will It Be Enough for Investors Right Now?
October 31, 2023
Via
The Motley Fool
Better Than Chemotherapy - AstraZeneca/Daiichi Sankyo Partnered Cancer Drug Meets Primary Goal In Breast Cancer Setting
September 22, 2023
Via
Benzinga
AstraZeneca's Reinforces Hold In Lung Cancer Settings: Touts Promising Data From Three Trials
September 11, 2023
Via
Benzinga
FDA Greenlights Daiichi Sankyo's Blood Cancer Drug, A Promising Competitor to Novartis' Rydapt
July 21, 2023
Via
Benzinga
Psyched: A $100M Donation Pledge, Frank Biden Gets Candid, New Search Trends & More
July 04, 2023
Via
Benzinga
AstraZeneca Shares Under Pressure On Some Adverse Events In Late-Stage Lung Cancer Drug Trial
July 03, 2023
Via
Benzinga
Japanese Pharma Company Sponsors Australian Start Up In Development Of Non-Hallucinogenic Medicines
June 27, 2023
Via
Benzinga
AstraZeneca-Daiichi Sankyo's Flagship Cancer Drug Shows Meaningful, Durable Responses In Other Solid Tumor Setting
March 06, 2023
Via
Benzinga
Is Gilead Sciences a Good Stock to Buy Now?
February 06, 2023
Via
The Motley Fool
AstraZeneca’s Next “Wonder Drug”
January 19, 2023
Via
Talk Markets
AstraZeneca - Daiichi Sankyo's Enhertu Wins European Approval For Gastric Cancer, CHMP Backs Other Cancer Drugs
December 19, 2022
Via
Benzinga
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.